Ligand Pharmaceuticals (LGND) Projected to Post Earnings on Thursday

Key Points

• Ligand Pharmaceuticals is set to announce its Q2 2025 earnings on August 7th, with expected earnings of $1.54 per share and revenues of $43.87 million.
• The company recently reported a quarterly earnings of $1.33 per share, which surpassed analysts' expectations of $1.23, alongside revenues of $45.33 million.
• Despite a negative return on equity of 7.83%, Ligand Pharmaceuticals has a market capitalization of $2.61 billion, with stock trading up 2.8% recently.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.54 per share and revenue of $43.87 million for the quarter. Ligand Pharmaceuticals has set its FY 2025 guidance at 6.000-6.250 EPS.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biotechnology company reported $1.33 earnings per share for the quarter, beating analysts' consensus estimates of $1.23 by $0.10. The business had revenue of $45.33 million for the quarter, compared to the consensus estimate of $37.84 million. Ligand Pharmaceuticals had a negative return on equity of 7.83% and a negative net margin of 73.07%. During the same quarter in the previous year, the company posted $3.84 earnings per share. On average, analysts expect Ligand Pharmaceuticals to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Performance

NASDAQ:LGND traded up $1.14 during trading hours on Friday, hitting $132.72. 155,992 shares of the company's stock traded hands, compared to its average volume of 184,848. The stock's fifty day moving average price is $118.18 and its two-hundred day moving average price is $112.79. The firm has a market cap of $2.56 billion, a P/E ratio of -18.64 and a beta of 0.85. Ligand Pharmaceuticals has a twelve month low of $90.29 and a twelve month high of $143.13.

Insider Transactions at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, CEO Todd C. Davis purchased 9,510 shares of the company's stock in a transaction dated Friday, May 9th. The shares were bought at an average price of $105.20 per share, for a total transaction of $1,000,452.00. Following the purchase, the chief executive officer directly owned 161,234 shares in the company, valued at $16,961,816.80. This trade represents a 6.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Andrew Reardon sold 500 shares of the firm's stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $114.08, for a total transaction of $57,040.00. Following the transaction, the insider owned 31,903 shares in the company, valued at $3,639,494.24. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,934 shares of company stock valued at $335,060 in the last quarter. Corporate insiders own 7.00% of the company's stock.

Hedge Funds Weigh In On Ligand Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. Jane Street Group LLC boosted its stake in shares of Ligand Pharmaceuticals by 176.2% during the 1st quarter. Jane Street Group LLC now owns 36,922 shares of the biotechnology company's stock worth $3,882,000 after acquiring an additional 23,553 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Ligand Pharmaceuticals by 9.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 55,327 shares of the biotechnology company's stock valued at $5,817,000 after acquiring an additional 4,926 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Ligand Pharmaceuticals by 8.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,660 shares of the biotechnology company's stock worth $1,121,000 after purchasing an additional 809 shares during the last quarter. AQR Capital Management LLC bought a new stake in Ligand Pharmaceuticals during the first quarter worth approximately $344,000. Finally, Royal Bank of Canada grew its holdings in Ligand Pharmaceuticals by 25.8% during the first quarter. Royal Bank of Canada now owns 6,120 shares of the biotechnology company's stock valued at $644,000 after purchasing an additional 1,256 shares during the last quarter. 91.28% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LGND. Stifel Nicolaus initiated coverage on Ligand Pharmaceuticals in a report on Thursday, April 10th. They issued a "buy" rating and a $143.00 target price on the stock. Oppenheimer raised their price target on shares of Ligand Pharmaceuticals from $145.00 to $162.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, Wall Street Zen lowered shares of Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $150.00.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.